<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969485</url>
  </required_header>
  <id_info>
    <org_study_id>HALOCIP002</org_study_id>
    <nct_id>NCT03969485</nct_id>
  </id_info>
  <brief_title>Hybrid Fractional Laser for Treatment of Off Face Body Skin Quality</brief_title>
  <official_title>Non-Randomized, Open-label, Blinded Evaluator Study Characterizing Effectiveness of Hybrid Fractional Laser for the Treatment of Off Face Body Skin Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate effectiveness of hybrid fractional laser for the treatment of poor skin&#xD;
      quality on the decolletage, back of the hands and lower legs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Actual">October 12, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photography</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate improvement in photography using Physicians Global Assessment Scale (0-4) where 0 is no change and 4 is very significant improvement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Skin Laxity</condition>
  <arm_group>
    <arm_group_label>Hybrid Fractional Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hybrid Fractional Laser Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Fractional Laser</intervention_name>
    <description>Hybrid Fractional Laser Device</description>
    <arm_group_label>Hybrid Fractional Laser</arm_group_label>
    <other_name>HALO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male/female subjects between 40 to 65 years of age inclusive&#xD;
&#xD;
          2. Fitzpatrick skin type I-III&#xD;
&#xD;
          3. Non-smokers or have not smoked (including vaping) within the past 14 days from the&#xD;
             screening visit&#xD;
&#xD;
          4. Has poor skin texture&#xD;
&#xD;
          5. Has mild thin skin&#xD;
&#xD;
          6. Has some level of dyschromia on the treatment area as assessed by the Investigator&#xD;
&#xD;
          7. Can read, understand and sign informed consent form (English only)&#xD;
&#xD;
          8. Has indicated willingness to participate in the study by signing an informed consent&#xD;
             form&#xD;
&#xD;
          9. Agrees to adhere to the treatment and follow-up schedule and post treatment care&#xD;
             instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fitzpatrick skin type IV-VI&#xD;
&#xD;
          2. Has tanned within the past 30 days or is unable or unlikely to refrain from tanning,&#xD;
             including the use of tanning booths, tanning spray or cream&#xD;
&#xD;
          3. Has tattoos, dysplastic nevi on the treatment area&#xD;
&#xD;
          4. Is pregnant and/or lactating&#xD;
&#xD;
          5. History or current photosensitivity&#xD;
&#xD;
          6. History or current use of medication with photosensitizing properties within past 6&#xD;
             months&#xD;
&#xD;
          7. History or current of chronic reoccurring skin disease or disorder affecting treatment&#xD;
             area&#xD;
&#xD;
          8. History or current cancer of any type&#xD;
&#xD;
          9. Has signs of actinic bronzing&#xD;
&#xD;
         10. Has open lacerations, and abrasions on the treatment area&#xD;
&#xD;
         11. History of keloid formation, or hypertrophic scar formation, or poor wound healing&#xD;
&#xD;
         12. History of bleeding disorder, or is currently taking anticoagulation medications&#xD;
&#xD;
         13. Has significant concurrent illnesses (controlled or uncontrolled), such as diabetes,&#xD;
             lupus, epilepsy, or cardiac disorders, which might be aggravated as a result of&#xD;
             treatment&#xD;
&#xD;
         14. Has participated in any clinical trial involving an investigational drug, device or&#xD;
             cosmetic product or procedure within the past 30 days&#xD;
&#xD;
         15. The investigator feels that for any reason the subject is not eligible to participate&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New Jersey Clinical Research Center</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

